reports
Completion of Share Buy-back Program
Completion of Share Buy-back Program Company Announcement COPENHAGEN, Denmark; June 30, 2025 – Genmab A/S (Nasdaq: GMAB) announces that its share buy-back program has been completed on June 26, 2025. On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back program was expected to be completed no later than July 10, 2025. The following transactions were executed under the program from June 23, 2025, to June 26, 2025: Tradi...
- ABGSC Energy Research
- Daniel Vårdal Haugland
- John Olaisen
- Njål Kleiven
- Oliver Dunvold
- Stian Wibstad
- ABGSC Oil & Oil Services Research
- John Olaisen
- ABGSC Energy Research
- Åsne Holsen
- Daniel Vårdal Haugland
- John Olaisen
- Stian Wibstad
TGS Webcast Details for Q2 2025 Presentation
TGS Webcast Details for Q2 2025 Presentation Oslo, Norway (26 June 2025) - TGS, a leading global provider of energy data and intelligence will release its Q2 2025 results at approximately 07:00 a.m. CEST on 17 July 2025. CEO Kristian Johansen and CFO Sven Børre Larsen will present the results at 09:00 a.m. CEST. The presentation is webcasted live. Access and registration for webcast attendees are available by copying and pasting the link below into your browser, or use the link on the front page of : /landingpage/hegnarmedia/20250717_2/ The Q2 2025 earnings release and presentation will ...
- ABGSC Oil & Oil Services Research
- John Olaisen
- Njål Kleiven
- Oliver Dunvold
- Stian Wibstad
EQNR EQUINOR ASA
AKAST AKASTOR ASA
KOG KONGSBERG GRUPPEN ASA
SOC SUBSEA 7 S.A.
PEN PANORO ENERGY ASA
ARCHERO ARCHER
AKER AKER ASA CLASS A
DNO DNO ASA CLASS A
TGS TGS-NOPEC GEOPHYSICAL COMPANY ASA
ODL ODFJELL DRILLING
AKSOO AKER SOLUTIONS ASA
BWO BW OFFSHORE LIMITED
PRS PROSAFE
OKEA OKEA
BWE BW ENERGY
VAR VAR ENERGI ASA
SEAPT-NO SEACREST PETROLEO
DOFG DOF GROUP ASA
Transactions in Connection with Share Buy-back Program
Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; June 23, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back program is expected to be completed no later than July 10, 2025. The following transactions were executed under the program from June 16 to June 20, 2025: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)Accumulat...
- ABGSC Energy Research
- Åsne Holsen
- Daniel Vårdal Haugland
- John Olaisen
- Stian Wibstad
- ABGSC Shipping & Transport Research
- Henrik Bartnes
- Petter Nystrøm
TGS and Viridien Announce Launch of Laconia Phase III OBN Survey in th...
TGS and Viridien Announce Launch of Laconia Phase III OBN Survey in the Gulf of America OSLO, Norway (19 June 2025) – TGS, a global leader in energy data and intelligence, in collaboration with Viridien, an advanced technology, digital and Earth data company, today announced the commencement of Laconia Phase III in the Gulf of America. This latest phase in the large-scale Laconia ocean bottom node (OBN) survey program spans approximately 150 OCS blocks and follows the well-received Laconia Phases I and II launched by Viridien in July 2024.The program will be acquired by TGS and provide Ult...
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Capital Increase in Genmab as a Result of Employee Warrant Exercise Company Announcement COPENHAGEN, Denmark; June 17, 2025 – (Nasdaq: GMAB) will increase its share capital by 32,117 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 27,396 shares at DKK 1,025.00,2,790 shares at DKK 1,050.00, 150 shares at DKK 1,147.50,1,557 shares at DKK 1,161.00, and224 shares at DKK 1,334.50. P...
Transactions with shares and linked securities in Genmab A/S made by m...
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons Company Announcement COPENHAGEN, Denmark; June 17, 2025 – (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to p...
Transactions in Connection with Share Buy-back Program
Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; June 16, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back program is expected to be completed no later than July 10, 2025. The following transactions were executed under the program from June 9 to June 13, 2025: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)Accumulate...
Genmab Announces Epcoritamab Investigational Combination Therapy Demon...
Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT) Media ReleaseCOPENHAGEN, Denmark; June 15, 2025 Results from the EPCORE® NHL-2 trial show investigational treatment with epcoritamab in combination with rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) led to an overall response rate (ORR) of 87 percent and a complete response (CR) rate of 65 percent in patients with relapsed or refractory (R/R) ...
- ABGSC Capital Goods Research
- Simon Brun
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Grant of Restricted Stock Units and Warrants to Employees in Genmab Company Announcement COPENHAGEN, Denmark; June 12, 2025 – (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 3,320 restricted stock units and 3,636 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on the date of grant of one Genmab A/S share, DKK...
NCC AB: 5 directors
Two Directors at NCC AB bought 2,178 shares at 190.874SEK. The significance rating of the trade was 58/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showin...
- ABGSC Energy Research
- Daniel Vårdal Haugland
- John Olaisen
- Njål Kleiven
- Oliver Dunvold
- Stian Wibstad
Transactions in Connection with Share Buy-back Program
Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; June 10, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back program is expected to be completed no later than July 10, 2025. The following transactions were executed under the program from June 2 to June 6, 2025: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)Accumulated...
- ABGSC Energy Research
- Daniel Vårdal Haugland
- John Olaisen
- Njål Kleiven
- Oliver Dunvold
- Stian Wibstad
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.